Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 288,266 | 308,636 | 401,590 | 397,433 | 453,932 |
| Receivables | 473,575 | 511,250 | 533,606 | 507,208 | 457,445 |
| Inventories | 381,877 | 389,804 | 379,958 | 390,599 | 380,282 |
| Other current assets | 256,179 | 224,054 | 213,458 | 206,733 | 203,595 |
| TOTAL | $1,399,897 | $1,433,744 | $1,528,612 | $1,501,973 | $1,495,254 |
| Non-Current Assets | |||||
| PPE Net | 713,123 | 717,745 | 708,178 | 708,725 | 702,177 |
| Intangibles | 516,776 | 518,956 | 518,833 | 524,024 | 450,461 |
| Other Non-Current Assets | 663,647 | 680,321 | 659,244 | 618,793 | 612,033 |
| TOTAL | $1,893,546 | $1,917,022 | $1,886,255 | $1,851,542 | $1,764,671 |
| Total Assets | $3,293,443 | $3,350,766 | $3,414,867 | $3,353,515 | $3,259,925 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 167,787 | 99,140 | 170,112 | 74,998 | 74,997 |
| Accounts payable and accrued liabilities | 114,211 | 110,603 | 117,468 | 117,462 | 110,643 |
| Accrued Expenses | 502,119 | 511,047 | 541,124 | 476,249 | 478,712 |
| TOTAL | $1,067,916 | $1,009,224 | $1,116,702 | $956,902 | $951,547 |
| Non-Current Liabilities | |||||
| Long Term Debt | 449,786 | 524,758 | 524,743 | 620,778 | 622,883 |
| Deferred Revenues | 33,799 | 38,434 | 37,998 | 38,193 | 37,195 |
| Other Non-Current Liabilities | 142,177 | 166,299 | 156,361 | 170,140 | 165,197 |
| TOTAL | $630,214 | $723,488 | $717,912 | $827,707 | $823,848 |
| Total Liabilities | $1,698,130 | $1,732,712 | $1,834,614 | $1,784,609 | $1,775,395 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 81,328 | 81,885 | 82,306 | 82,587 | 83,089 |
| Common Shares | 10,784 | 10,770 | 10,769 | 10,767 | 10,751 |
| Retained earnings | 5,332,438 | 5,116,289 | 4,883,448 | 4,680,150 | 4,444,571 |
| Other shareholders' equity | -87,772 | -70,368 | -79,415 | -74,760 | -65,357 |
| TOTAL | $1,595,313 | $1,618,054 | $1,580,253 | $1,568,906 | $1,484,530 |
| Total Liabilities And Equity | $3,293,443 | $3,350,766 | $3,414,867 | $3,353,515 | $3,259,925 |